Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Plus, the FT’s southeast Europe correspondent, Valerie Hopkins, explains the love-hate relationships that Serbians have with Chinese investment in their country....
...It appears that we have our “V”. The start of the month on Thursday brought with it the usual slew of updates on the health of the world economy, and they appeared to be in agreement....
...“Our competitors get into these brand wars like Coke v Pepsi,” says Zimmer at UTA....
International Edition